Sex hormone‐binding globulin (<scp>SHBG</scp>) is a potential early diagnostic biomarker for gastric cancer

Cheng, Chao; Chang, Che-Chang; Patria, Yudha Nur; Chang, Ruei Ting; Liu, Yun Ru; Li, Fu An; Shih, Hsiu Ming; Lin, Ching Yu

doi:10.1002/cam4.1254

Cited by 22 publications

(12 citation statements)

References 46 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 Speculatively, this could perhaps be due to the role of SHBG in limiting estradiol bioactivity, as estradiol has been shown to reduce the viability and carcinogenic potential of Helicobacter pylori in animal models. 44,45 Nevertheless, we are unable to rule out the possibility of reverse causation 46 or chance.…”

Section: Associations With Incident Cancer In Menmentioning

confidence: 85%

Prospective analyses of testosterone and sex hormone‐binding globulin with the risk of 19 types of cancer in men and postmenopausal women in UK Biobank

Watts

Pérez-Cornago

Tsilidis

et al. 2021

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

Section: Associations With Incident Cancer In Menmentioning

confidence: 85%

Prospective analyses of testosterone and sex hormone‐binding globulin with the risk of 19 types of cancer in men and postmenopausal women in UK Biobank

Watts

Pérez-Cornago

Tsilidis

et al. 2021

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Speculatively, this may be due to the role of SHBG in limiting estradiol bioactivity, as estradiol has been shown to reduce the viability and carcinogenic potential of H. pylori in animal models (46,47). Nevertheless, we are unable to rule-out the possibility of reverse causation (48) or chance.…”

Section: Associations With Incident Cancer In Menmentioning

confidence: 88%

Free testosterone and malignant melanoma risk in men: prospective analyses of testosterone and SHBG with 19 cancers in men and postmenopausal women UK Biobank

Watts

Pérez-Cornago

Knüppel

et al. 2020

Preprint

View full text Add to dashboard Cite

We investigated the associations of estimated free and total circulating testosterone and sex hormone-binding globulin (SHBG) with cancer risk in men and postmenopausal women, using a pan-cancer approach, including 19 cancers in UK Biobank.Risk was estimated using multivariable-adjusted Cox regression in up to 182,608 men and 122,112 postmenopausal women who were cancer-free at baseline. Participants diagnosed with cancer within two years of baseline were excluded. Hazard ratios (HRs) and confidence intervals (CIs) were corrected for regression dilution bias using repeat measurements. We accounted for multiple testing using the false discovery rate.In men, higher free testosterone was associated with higher risks of melanoma and prostate cancer (HR per 50 pmol/L increase=1.35, 95% CI 1.14-1.61 and 1.10,1.04-1.18, respectively). Higher total testosterone was associated with an elevated risk of liver cancer (HR per 5 nmol/L=2.45,1.56-3.84), and higher SHBG was associated with a higher risk of liver cancer (HR per 10 nmol/L=1.56,1.31-1.87) and a lower risk of prostate cancer (0.93,0.91-0.96); associations with liver cancer were attenuated after excluding early follow-up. In postmenopausal women, higher free and total testosterone and lower SHBG were associated with elevated risks of endometrial (HR per 10 pmol/L=1.59,1.32-1.90; HR per 0.5 nmol/L=1.34,1.18-1.52 and HR per 25 nmol/L=0.78,0.67-0.91, respectively) and breast cancer (1.32,1.22-1.43;1.24,1.17-1.31 and 0.88,0.83-0.94, respectively).We report a novel association of free testosterone with malignant melanoma in men; our findings also support known associations between sex hormones and risks for prostate, breast and endometrial cancers. The association with liver cancer in men may be attributable to reverse causation.

show abstract

“…There are few reports that have investigated the association between SHBG and cancers. For example, Cheng and colleagues reported that plasma levels of SHBG are significantly increased in patients with gastric cancer, whereas Huang and colleagues suggested that higher expression of SHBG in ovarian cancer is a poor prognostic factor (38,39). Being female gender has been reported as a poor prognostic factor in patients with NMIBC (3,40).…”

Section: Discussionmentioning

confidence: 99%

Urinary Cytokine Profile to Predict Response to Intravesical BCG with or without HS-410 Therapy in Patients with Non–muscle-invasive Bladder Cancer

Salmasi

Elashoff

Guo

et al. 2019

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: Despite extensive research to identify biomarkers of response in patients with non-muscle-invasive bladder cancer (NMIBC), there is no biomarker to date that can serve this purpose. Herein, we report how we leveraged serial urine samples to query a panel of cytokines at varying time points in an attempt to identify predictive biomarkers of response in NMIBC. Methods: Serial urine samples were collected from 50 patients with intermediate-or high-risk NMIBC enrolled in a phase II study, evaluating intravesical BCG AE intradermal HS-410 therapy. Samples were collected at baseline, week 7, week 13, week 28, and at end of treatment. A total of 105 cytokines were analyzed in each sample. To predict outcome of time-to-event (recurrence or progression), univariate and multivariable Cox analyses were performed. Results: Fifteen patients developed recurrence and 4 patients progressed during the follow-up period. Among clin-icopathologic variables, ever-smoker versus nonsmoker status was associated with an improved response rate (HR 0.38; 95% confidence interval (CI), 0.14-0.99; P ¼ 0.04). In the most clinically relevant model, the percent change (for 100 units) of IL18-binding protein-a (HR 1.995; 95% CI, 1.16-3.44; P ¼ 0.01), IL23 (HR 1.12; 95% CI, 1.01-1.23; P ¼ 0.03), IL8 (HR 0.27; 95% CI, 0.07-1.08; P ¼ 0.06), and IFNg-induced protein-10 (HR 0.95; 95% CI, 0.91-0.99; P ¼ 0.04) at week 13 from baseline best predicted time to event. Conclusions: Urinary cytokines provided additional value to clinicopathologic features to predict response to immunemodulating agents in patients with NMIBC. Impact: This study serves as a hypothesis-generating report for future studies to evaluate the role of urine cytokines as a predictive biomarker of response to immune treatments.

show abstract

Sex hormone‐binding globulin (SHBG) is a potential early diagnostic biomarker for gastric cancer

Cited by 22 publications

References 46 publications

Prospective analyses of testosterone and sex hormone‐binding globulin with the risk of 19 types of cancer in men and postmenopausal women in UK Biobank

Prospective analyses of testosterone and sex hormone‐binding globulin with the risk of 19 types of cancer in men and postmenopausal women in UK Biobank

Free testosterone and malignant melanoma risk in men: prospective analyses of testosterone and SHBG with 19 cancers in men and postmenopausal women UK Biobank

Urinary Cytokine Profile to Predict Response to Intravesical BCG with or without HS-410 Therapy in Patients with Non–muscle-invasive Bladder Cancer

Contact Info

Product

Resources

About